Anorexigenic Lipopeptides Ameliorate Central Insulin Signaling and Attenuate Tau Phosphorylation in Hippocampi of Mice with Monosodium Glutamate-Induced Obesity

Journal of Alzheimer's Disease

Volumn 45, Issue 3, 2015, Pages 823-835

  Špolcová, Andrea ^a,b,g   Mikulášková, Barbora ^a   Holubová, Martina ^a   Nagelová, Veronika ^a   Pirnik, Zdenko ^a,e,f   Zemenová, Jana ^a,d   Haluzík, Martin ^c   Železná, Blanka ^a   Galas, Marie Christine ^b,g   Maletínská, Lenka ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b INSERM   (France)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^e INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^f UNIVERSITY OF VETERINARY MEDICINE   (Slovakia)

^g UNIV LILLE   (France)

Author keywords

Alzheimer's disease; insulin signaling; liraglutide; monosodium glutamate obese mice; obesity; pre diabetes; prolactin releasing peptide; tau phosphorylation

Indexed keywords

ANOREXIGENIC AGENT; GLUTAMATE SODIUM; INSULIN; LIPOPEPTIDE; LIRAGLUTIDE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROLACTIN RELEASING FACTOR; PROTEIN KINASE B; SERINE; TAU PROTEIN; THREONINE; FLAVORING AGENT; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; INSULIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FOOD INTAKE; HIPPOCAMPUS; HYPOTHALAMUS; INSULIN RELEASE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; FLAVORING AGENTS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HIPPOCAMPUS; INSULINS; LIPOPEPTIDES; MALE; MICE; OBESITY; PHOSPHORYLATION; PROLACTIN-RELEASING HORMONE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SODIUM GLUTAMATE; TAU PROTEINS; TIME FACTORS;

EID: 84925821657     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143150     Document Type: Article

References (50)

1. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F (2013) Tau protein kinases: Involvement in Alzheimer's disease. Ageing Res Rev 12, 289-309.
2. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95-130.
3. Kolarova M, Garcia-Sierra F, Bartos A, Ricny J, Ripova D (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012, 731526.
4. Lee G, Leugers CJ (2012) Tau and tauopathies. Prog Mol Biol Transl Sci 107, 263-293.
5. Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J, Ramachandran D, Poidinger M, Karran E, Davies P, Hutton M, Szekeres P, Bose S (2013) An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem 288, 23331-23347.
6. Tenreiro S, Eckermann K, Outeiro TF (2014) Protein phosphorylation in neurodegeneration: Friend or foe? Front Mol Neurosci 7, 42.
7. Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269, 14566-14574.
8. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225, 54-62.
9. Kim B, Backus C, Oh S, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150, 5294-5301.
10. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, Perdomo G, Spires-Jones T, Cozar-Castellano I, Lechuga-Sancho AM, Garcia-Alloza M (2013) Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 38, 2462-2475.
11. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86, 3265-3274.
12. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med 15, 102-114.
13. McClean PL, Parthsarathy V, Faivre E, Hölscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31, 6587-6594.
14. Faivre E, Holscher C (2013) Neuroprotective effects of DAla(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther 5, 20.
15. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19, 1205-1219.
16. Yarchoan M, Arnold SE (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63, 2253-2261.
17. Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112, 1199-1208.
18. Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ (2012) (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 674, 280-286.
19. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ (2014) Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 124, 2456-2463.
20. Dodd GT, Luckman SM (2013) Physiological Roles of GPR10 and PrRP Signaling. Front Endocrinol (Lausanne 4, 20.
21. Ellacott K, Lawrence C, Rothwell N, Luckman S (2002) PRLreleasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology 143, 368-374.
22. Greco SJ, Sarkar S, Johnston JM, Tezapsidis N (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380, 98-104.
23. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N, Casadesus G (2010) Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 19, 1155-1167.
24. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N (2004) Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18, 1870-1878.
25. Kamal A, Ramakers GM, Gispen WH, Biessels GJ (2013) Hyperinsulinemia in rats causes impairment of spatial memory and learning with defects in hippocampal synaptic plasticity by involvement of postsynaptic mechanisms. Exp Brain Res 226, 45-51.
26. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T (2002) Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113, 607-615.
27. Djazayery A, Miller DS, Stock MJ (1979) Energy balances in obese mice. Nutr Metab 23, 357-367.
28. Maletínská L, Toma RS, Pirnik Z, Kiss A, Slaninová J, Haluzík M, Zelezná B (2006) Effect of cholecystokinin on feeding is attenuated in monosodium glutamate obese mice. Regul Pept 136, 58-63.
29. Remke H, Wilsdorf A, Müller F (1988) Development of hypothalamic obesity in growing rats. Exp Pathol 33, 223-232.
30. Blechová M, Nagelová V, Záková L, Demianová Z, Zelezná B, Maletínská L (2013) New analogs of the CART peptide with anorexigenic potency: The importance of individual disulfide bridges. Peptides 39, 138-144.
31. Maletínsk á L, Pýchová M, Holubová M, Blechov á M, Demianová Z, Elbert T, Železná B (2012) Characterization of new stable ghrelin analogs with prolonged orexigenic potency. J Pharmacol Exp Ther 340, 781-786.
32. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buee L, Galas MC (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286, 4566-4575.
33. Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates, New York: Academic Press.
34. Maletinska L, Nagelova V, Ticha A, Spolcova A, Blechova M, Pirnik Z, Kunes J, Zelezna B (2013) Lipidized analogs of prolactin-releasing peptide reduce food intake in rodents after peripheral administration. Biopolymers 100, 255-255.
35. Takasaki Y (1978) Studies on brain lesion by administration of monosodium L-glutamate to mice. I. Brain lesions in infant mice caused by administration of monosodium L-glutamate. Toxicology 9, 293-305.
36. Matysková R, Maletínská L, Maixnerová J, Pirník Z, Kiss A, Zelezná B (2008) Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice. Physiol Res 57, 727-734.
37. Cameron DP, Poon TK, Smith GC (1976) Effects of monosodium glutamate administration in the neonatal period on the diabetic syndrome in KK mice. Diabetologia 12, 621-626.
38. Lorden JF, Sims JS (1987) Monosodium L-glutamate lesions reduce susceptibility to hypoglycemic feeding and convulsions. Behav Brain Res 24, 139-146.
39. Spolcova A, Mikulaskova B, Krskova K, Gajdosechova L, Zorad S, Olszanecki R, Suski M, Bujak-Gizycka B, Zelezna B, Maletinska L (2014) Deficient hippocampal insulin signaling and augmented tau phosphorylation is related to obesity- and age-induced peripheral insulin resistance: A study in Zucker rats. BMC Neurosci 15, 111.
40. Su JH, Cummings BJ, Cotman CW (1994) Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport 5, 2358-2362.
41. Bonda DJ, Stone JG, Torres SL, Siedlak SL, Perry G, Kryscio R, Jicha G, Casadesus G, Smith MA, Zhu X, Lee HG (2014) Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance. J Neurochem 128, 162-172.
42. Doherty GH, Beccano-Kelly D, Yan SD, Gunn-Moore FJ, Harvey J (2013) Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta. Neurobiol Aging 34, 226-237.
43. Ellacott KL, Lawrence CB, Rothwell NJ, Luckman SM (2002) PRL-releasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology 143, 368-374.
44. Hunter K, Holscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13, 33.
45. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9, 1173-1179.
46. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX (2013) Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 37, 637-648.
47. Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA (2010) Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 12, 891-899.
48. Lennox R, Porter DW, Flatt PR, Gault VA (2013) (Val(8))GLP-1-Glu-PAL: A GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and beta-cell function in high-fat-fed mice. ChemMedChem 8, 595-602.
49. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4, e7917.
50. Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D (2013) Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes 62, 1681-1688.